We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$1.26M
Cap. Flow %
0.25%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 4.38%
3 Communication Services 1.99%
4 Industrials 1.8%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$57.2M 11.17%
8,000
-542,000
-99% -$35.7M
CELG
2
DELISTED
Celgene Corp
CELG
$31.1M 6.08%
250,000
+70,000
+39% +$8.38M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$23.8M 4.65%
+1,000
New +$232K
BIIB icon
4
Biogen
BIIB
$30B
$20.5M 4.01%
+75,000
New +$21.2M
NVS icon
5
Novartis
NVS
$297B
$19M 3.71%
+284,580
New +$19M
MRK icon
6
Merck
MRK
$322B
$18.7M 3.66%
309,160
-162,440
-34% -$9.86M
SHPG
7
DELISTED
Shire pic
SHPG
$15.4M 3.02%
214,539
+182,039
+560% +$31.8M
CELG
8
CALL
DELISTED
Celgene Corp
CELG
$14.9M 2.91%
+1,200
New +$144K
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$14.3M 2.8%
483,047
+85,000
+21% +$2.63M
PFE icon
10
Pfizer
PFE
$143B
$13.3M 2.61%
+411,060
New +$13M
ITRN icon
11
Ituran Location and Control
ITRN
$1.09B
$8.68M 1.7%
281,356
-25,277
-8% -$713K
BMY icon
12
Bristol-Myers Squibb
BMY
$133B
$8.16M 1.59%
+150,000
New +$8.23M
NBIX icon
13
PUT
Neurocrine Biosciences
NBIX
$16.8B
$8.01M 1.57%
+1,500
New +$64.3K
ASND icon
14
Ascendis Pharma A/S
ASND
$16B
$7.15M 1.4%
255,455
-71,167
-22% -$1.8M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.09M 1.39%
480,000
+180,000
+60% +$2.92M
OEF icon
16
PUT
iShares S&P 100 ETF
OEF
$20.1B
$6.95M 1.36%
500
-111,500
-100% -$11.5M
NBIX icon
17
Neurocrine Biosciences
NBIX
$16.8B
$6.5M 1.27%
+150,000
New +$6.43M
ARAV
18
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.41M 1.25%
50,000
+8,333
+20% +$879K
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$6.26M 1.22%
700,000
-200,000
-22% -$2.13M
IMMU
20
DELISTED
Immunomedics Inc
IMMU
$6.15M 1.2%
950,000
-100,000
-10% -$507K
CRVS icon
21
Corvus Pharmaceuticals
CRVS
$1.12B
$5.8M 1.13%
279,166
-41,063
-13% -$643K
TEVA icon
22
Teva Pharmaceuticals
TEVA
$40.8B
$5.52M 1.08%
172,000
-350,000
-67% -$11.9M
ORBK
23
DELISTED
Orbotech Ltd
ORBK
$5.07M 0.99%
157,096
+111,875
+247% +$3.62M
AKAO
24
DELISTED
Achaogen Inc
AKAO
$5.05M 0.99%
200,000
-314,342
-61% -$6.46M
TEVA icon
25
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$4.74M 0.93%
1,500
-213,500
-99% -$7.29M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2017 filing shows 35 new, 30 increased, 28 reduced and 26 closed positions. Its largest new stake was Biogen: 75,000 shares worth $20.5M. The largest sale was Alexion Pharmaceuticals, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 61% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceuticals, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.